{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:33:29Z","timestamp":1762504409712,"version":"build-2065373602"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008659","name":"European Committee for Treatment and Research in Multiple Sclerosis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eNeurologicalSci"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.ensci.2020.100279","type":"journal-article","created":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T01:08:27Z","timestamp":1602205707000},"page":"100279","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Severe lymphopenia after subcutaneous cladribine in a patient with multiple sclerosis: To vaccinate or not?"],"prefix":"10.1016","volume":"21","author":[{"given":"M.","family":"Mateo-Casas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"De Trane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Espasandin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Anjorin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Schmierer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Giovannoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ensci.2020.100279_bb0005","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"S2","key":"10.1016\/j.ensci.2020.100279_bb0010","first-page":"42","article-title":"Cladribine personalised dosing in people with MS (n>200) four years experience in clinical care","volume":"24","author":"De Trane","year":"2018","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.ensci.2020.100279_bb0015","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1136\/jnnp-2017-317411","article-title":"Cladribine: mechanisms and mysteries in multiple sclerosis","volume":"89","author":"Jacobs","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ensci.2020.100279_bb0020","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1177\/1352458510391344","article-title":"Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study","volume":"17","author":"Cook","year":"2011","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.ensci.2020.100279_bb0025","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1474-4422(14)70005-5","article-title":"Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial","volume":"13","author":"Leist","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ensci.2020.100279_bb0030","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.msard.2018.11.001","article-title":"Treating the ineligible: disease modification in people with multiple sclerosis beyond NHS England commissioning policies","volume":"27","author":"Mao","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.ensci.2020.100279_bb0035","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1177\/1352458509103610","article-title":"Effect of parenteral cladribine on relapse rates in patients with relapsing forms of multiple sclerosis: results of a 2-year, double-blind, placebo-controlled, crossover study","volume":"15","author":"S","year":"2009","journal-title":"Mult. Scler."},{"key":"10.1016\/j.ensci.2020.100279_bb0040","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.jiph.2019.05.017","article-title":"Dynamic changes of lymphocyte counts in adult patients with severe pandemic H1N1 influenza A","volume":"12","author":"Cheng","year":"2019","journal-title":"J. Infect. Pub. Health"},{"key":"10.1016\/j.ensci.2020.100279_bb0045","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/23744235.2019.1598572","article-title":"Severe lymphopenia in hospitalized patients with influenza virus infection as a marker of a poor outcome","volume":"51","author":"Lalueza","year":"2019","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.ensci.2020.100279_bb0050","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing\u2013remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.ensci.2020.100279_bb0055","series-title":"Vaccines Against Influenza WHO Position Paper - November 2012","first-page":"461","volume":"vol. 87","author":"World Health Organization (WHO)","year":"2012"},{"key":"10.1016\/j.ensci.2020.100279_bb0060","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.90.15_supplement.S36.002","article-title":"Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis","volume":"90","author":"Stokmaier","year":"2018","journal-title":"Neurology"},{"year":"2017","series-title":"Immunisation Against Infectious Disease (The Green Book)","author":"Public Health England","key":"10.1016\/j.ensci.2020.100279_bb0065"},{"author":"Compendium electronic medicines","key":"10.1016\/j.ensci.2020.100279_bb0070"}],"container-title":["eNeurologicalSci"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405650220300587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405650220300587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:19:30Z","timestamp":1762503570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405650220300587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":14,"alternative-id":["S2405650220300587"],"URL":"https:\/\/doi.org\/10.1016\/j.ensci.2020.100279","relation":{},"ISSN":["2405-6502"],"issn-type":[{"type":"print","value":"2405-6502"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe lymphopenia after subcutaneous cladribine in a patient with multiple sclerosis: To vaccinate or not?","name":"articletitle","label":"Article Title"},{"value":"eNeurologicalSci","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ensci.2020.100279","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100279"}}